Gene therapeutic DNA vector based on VTvaf17 gene therapeutic DNA vector carrying a target gene selected from the group of genes ANG, ANGPT1, VEGFA, FGF1, HIF1α, HGF, SDF1, KLK4, PDGFC, PROK1, PROK2 to increase the expression level of these target genes, method its preparation and use, Escherichia coli strain SCS110-AF / VTvaf17-ANG or Escherichia coli SCS110-AF / VTvaf17-ANGPT1 or Escherichia coli SCS110-AF / VTvaf17-VEGFA or Escherichia coli SCS110-AF / VTvaf17-Fichia-SC110 AF / VTvaf17-HIF1α or Escherichia coli SCS110-AF / VTvaf17-HGF or Escherichia coli SCS110-AF / VTvaf17-SDF1 or Escherichia coli SCS110-AF / VTvaf17-KLK4 or Escherichia coli SCS110-AF / VTviFi10 SCF110 AF / VTvaf17-PROK1 or Escherichia coli SCS110-AF / VTvaf17-PROK2 carrying a gene therapy DNA vector, a method for its preparation, a method for the industrial production of a gene therapy DNA vector

摘要

The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaflV gene therapy DNA vector is proposed that carries a target gene selected from the group of genes ANG, ANGPT1, VEGFA, FGF1, HIFla, HGF, SDF1, KFK4, PDGFC, PROK1, PROK2, to increase the expression level of this target gene in humans and animals. Gene therapy DNA vector VTvafl7-ANG or VTvaf 17- AN GPT 1 or VTvafl7-VEGFA or VTvafl7-FGFl or VTvafl7-HIFla or VTvafl7-HGF or VTvafl7-SDFl or VTvaf 17-KFK4 or VTvaf 17-PDGFC, or VTvaf 17-PDKFC or VTvafl7 has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8 or SEQ ID No. 9 or SEQ ID No. 10 or SEQ ID No. 11, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.